ClinicalTrials.gg
RecruitingNCT07433387Updated May 11, 2026

Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals

A Phase 1/2 interventional study of LP-98 20 mg and LP-98 40 mg in HIV, sponsored by Shanxi Kangbao Biological Product Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Shanxi Kangbao Biological Product Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

An Exploratory Multicenter, Open-label, Sequential Cohort Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetic Characteristics of LP-98 for Injection in Antiretroviral Therapy-Naive HIV-Infected Individuals

Read the detailed description

The study utilizes a sequential cohort design, with three dosage cohorts (20 mg, 40 mg, 80 mg). The cohorts will be enrolled sequentially from low to high doses, with the next dose group initiating subject screening and enrollment after the last subject in the previous cohort has been enrolled.

The study plans to enroll a total of 30 subjects, with 10 subjects in each cohort. Enrolled subjects will receive LP-98 treatment at doses of 20 mg, 40 mg, or 80 mg according to their assigned cohort. The drug will be administered via subcutaneous injection, with an interval of 14 days between doses, for a total of 4 doses.

The study includes a screening phase (D-28 to D-1), a treatment phase (D1 to D57), and a follow-up phase (D58 to D71). The total duration of participation for each subject is approximately 99 days.

02

Conditions studied

  • HIV

Keywords

  • LP-98
03

In context

Lead sponsor

Shanxi Kangbao Biological Product Co., Ltd. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must voluntarily agree to participate in the study and provide before undergoing any study-related assessments.
  2. At the time of screening, the subject must be between 18 and 65 years of age (inclusive), either male or female.
  3. At the time of screening, male subjects must weigh at least 50 kg, and female subjects must weigh at least 45 kg.
  4. Plasma RNA levels must be ≥1000 copies/mL, and must be ≥200 cells/μL.
  5. For Female Subjects: Only non-reproductive females will be included, which includes those who have undergone surgical sterilization (documented hysterectomy or bilateral oophorectomy) at least 6 weeks prior to the screening visit, or those who have been for at least 12 months (confirmed by a follicle-stimulating hormone (FSH) level ≥40 IU/L).
  6. For Male Subjects with Fertile Female Partners: The subject must agree to use a non-pharmacological method for 14 days prior to dosing, during the study, and for 3 months following the administration of the study drug. Male subjects must not donate sperm during this period.
  7. The subject must be willing to adhere to the study protocol, including visits, study treatment, laboratory tests, and other study-related procedures and requirements.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to the study drug or its , or a history of severe allergic reactions (including any food allergies or drug allergies).
  2. Has previously received antiviral therapy (ART) or has been vaccinated against .
  3. A history of severe disease or the presence of other severe chronic conditions.
  4. A history of mental health disorders or a family history of psychiatric diseases.
  5. Any of the Following Conditions:

1)Persistent unexplained fever above 38°C within 1 month prior to screening or during the screening phase.

2)Persistent diarrhea (more than 3 bowel movements per day) within 1 month prior to screening or during the screening phase.

3)Severe infections, opportunistic infections, or sepsis within 6 months prior to screening or during the screening phase.

6、Positive for surface antigen (HBsAg) or antibody (HCV-Ab).

7、Abnormal 12-lead (ECG) findings with clinical significance at screening, such as a male interval (Fridericia correction formula) > 450 ms, or female QTcF > 470 ms.

8、Elevated (ALT) or aspartate aminotransferase (AST) > 1.5 times the (ULN), or total > 1.5 times ULN at screening.

9、Serum (Ccr) \< 60 mL/min at screening (calculated using the Cockcroft-Gault formula).

10、Known or suspected history of drug abuse (including morphine, methamphetamine, ketamine, dimethylthioamphetamine, tetrahydrocannabinolic acid, cocaine), or a positive baseline drug screening test.

11、A history of alcohol abuse within the past year (defined as consuming more than 14 standard units of alcohol per week, where 1 standard unit is 14 g of alcohol, equivalent to 360 mL of 5% beer, 45 mL of 40% liquor, or 120 mL of 12% wine), or inability to comply with the study's alcohol prohibition during the study.

12、Smoking more than 5 cigarettes per day within the last 3 months prior to screening, or inability to comply with the study's smoking prohibition during the study.

13、Receiving any vaccine within 3 months prior to screening, or planning to receive any vaccine during the study.

14、Received any drug treatment or participated in any drug/device trial (excluding in vitro diagnostic devices) within 3 months prior to dosing.

15、Major surgery within 30 days prior to dosing, or planned major surgery during the study.

16、Blood donation or loss of ≥ 400 mL within 3 months prior to screening, or receiving a blood transfusion during this period.

17、Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    LP-98 20 mg dose group

    A total of 10 subjects are planned to be enrolled in this cohort, and each enrolled subject will receive a 20 mg dose of LP-98 per administration. The drug will be administered via subcutaneous injection at an interval of 14 days, for a total of 4 administrations.

    Drug: LP-98 20 mg

  • Experimental
    LP-98 40 mg dose group

    A total of 10 subjects are planned to be enrolled in this cohort, and each enrolled subject will receive a 40 mg dose of LP-98 per administration. The drug will be administered via subcutaneous injection at an interval of 14 days, for a total of 4 administrations.

    Drug: LP-98 40 mg

  • Experimental
    LP-98 80 mg dose group

    A total of 10 subjects are planned to be enrolled in this cohort, and each enrolled subject will receive a 80 mg dose of LP-98 per administration. The drug will be administered via subcutaneous injection at an interval of 14 days, for a total of 4 administrations.

    Drug: LP-98 80 mg

Interventions

  • DrugLP-98 20 mg

    The study plans to enroll a total of 30 subjects, with 10 subjects in each cohort. Enrolled subjects will receive LP-98 treatment at doses of 20 mg, 40 mg, or 80 mg according to their assigned cohort. The drug will be administered via subcutaneous injection, with an interval of 14 days between doses, for a total of 4 doses.

  • DrugLP-98 40 mg

    LP-98 40 mg

  • DrugLP-98 80 mg

    LP-98 80 mg

06

What researchers measure

Primary outcomes

  1. Plasma HIV RNA levels (log10 copies/mL) and changes from baseline

    Changes of HIV viral load detection will be recorded.

    Time frame: Within 71 days after the first administration.

  2. Proportion of subjects with plasma HIV RNA < 50 copies/mL

    Changes of HIV viral load detection will be recorded.

    Time frame: Within 71 days after the first administration.

  3. Proportion of subjects with plasma HIV RNA < 200 copies/mL

    Changes of HIV viral load detection will be recorded.

    Time frame: Within 71 days after the first administration.

  4. Absolute CD4+ T lymphocyte count and change from baseline

    Changes of CD4+T counts will be recorded.

    Time frame: Within 71 days after the first administration.

  5. CD4+/CD8+ T lymphocyte ratio and change from baseline

    Changes of CD4+/CD8+ T counts will be recorded.

    Time frame: Within 71 days after the first administration.

Secondary outcomes

  1. Changes from baseline in respiration rate of Vital Signs.

    Respiration rate in times / minute

    Time frame: Within 71 days after the first administration.

  2. Changes from baseline in blood pressure of Vital Signs.

    Blood pressure in mmHg

    Time frame: Within 71 days after the first administration.

  3. Changes from baseline in Blood lactate of Laboratory Examination.

    Changes of blood lactate will be recorded.

    Time frame: Within 71 days after the first administration.

  4. Changes from baseline in body temperature of Vital Signs.

    Body temperature in Celsius degree

    Time frame: Within 71 days after the first administration.

  5. Changes from baseline in red blood cell count of Laboratory Examination.

    Red blood cell count in whole blood is reported in the form of number.

    Time frame: Within 71 days after the first administration.

  6. Changes from baseline in white blood cell count of Laboratory Examination.

    White blood cell count in whole blood is reported in the form of number.

    Time frame: Within 71 days after the first administration.

  7. Changes from baseline in neutrophil count of Laboratory Examination.

    Neutrophil count in whole blood is reported in the form of number.

    Time frame: Within 71 days after the first administration.

  8. Changes from baseline in lymphocyte count of Laboratory Examination.

    Lymphocyte count in whole blood is reported in the form of number.

    Time frame: Within 71 days after the first administration.

  9. Changes from baseline in platelet count of Laboratory Examination.

    Platelet count in whole blood is reported in the form of number.

    Time frame: Within 71 days after the first administration.

  10. Changes from baseline in hemoglobin of Laboratory Examination.

    Changes of hemoglobin concentration(g/dL)in whole blood will be recorded.

    Time frame: Within 71 days after the first administration.

  11. Changes from baseline in PT of Laboratory Examination.

    Prothrombin time (PT) is a screening test for exogenous coagulation factors.

    Time frame: Within 71 days after the first administration.

  12. Changes from baseline in INR of Laboratory Examination.

    International standardized ratio (INR) is calculated from prothrombin time and international sensitivity index (ISI) of the reagent.

    Time frame: Within 71 days after the first administration.

  13. Changes from baseline in APTT of Laboratory Examination.

    Activated partial thromboplastin time (APTT) is a screening test for endogenous coagulation factors.

    Time frame: Within 71 days after the first administration.

  14. Changes from baseline in total bilirubin of Laboratory Examination.

    Changes of total bilirubin concentration (μmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  15. Changes from baseline in direct bilirubin of Laboratory Examination.

    Changes of direct bilirubin concentration (μmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  16. Changes from baseline in ALT of Laboratory Examination.

    Changes of ALT concentration (U/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  17. Changes from baseline in AST of Laboratory Examination.

    Changes of AST concentration (U/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  18. Changes from baseline in total protein of Laboratory Examination.

    Changes of total protein concentration (g/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  19. Changes from baseline in albumin of Laboratory Examination.

    Changes of albumin concentration (g/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  20. Changes from baseline in urea of Laboratory Examination.

    Changes of urea concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  21. Changes from baseline in creatinine of Laboratory Examination.

    Changes of creatinine concentration (μmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  22. Changes from baseline in uric acid of Laboratory Examination.

    Changes of uric acid concentration (μmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  23. Changes from baseline in glucose of Laboratory Examination

    Changes of glucose concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  24. Changes from baseline in potassium of Laboratory Examination.

    Changes of potassium concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  25. Changes from baseline in sodium of Laboratory Examination.

    Changes of sodium concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  26. Changes from baseline in chlorine of Laboratory Examination.

    Changes of chlorine concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  27. Changes from baseline in urine specific gravity of Laboratory Examination.

    Changes of urine specific gravity will be recorded.

    Time frame: Within 71 days after the first administration.

  28. Changes from baseline in urine pH of Laboratory Examination.

    Changes of urine pH value will be recorded.

    Time frame: Within 71 days after the first administration.

  29. Changes from baseline in urine glucose of Laboratory Examination.

    Changes of urine glucose will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  30. Changes from baseline in urine protein of Laboratory Examination.

    Changes of urine protein will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  31. Changes from baseline in urine ketone body of Laboratory Examination.

    Changes of urine ketone body will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  32. Changes from baseline in urine white blood cell of Laboratory Examination.

    Changes of white blood cell in urine will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  33. Changes from baseline in urine bilirubin of Laboratory Examination.

    Changes of urine bilirubin will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  34. Changes from baseline in urine occult blood of Laboratory Examination.

    Changes of urine occult blood will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  35. Changes from baseline in Electrocardiogram.

    The cardiac rhythm is showed in electrocardiogram in the form of continuous curve.

    Time frame: Within 71 days after the first administration.

  36. Changes from baseline in CK of Laboratory Examination

    Changes of CK concentration (U/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  37. Changes from baseline in CK-MB of Laboratory Examination

    Changes of CK-MB concentration (ng/mL) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  38. Changes from baseline in LDH of Laboratory Examination

    Changes of LDH concentration (U/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  39. Changes from baseline in ALP of Laboratory Examination

    Changes of ALP concentration (U/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  40. Changes from baseline in Triglyceride of Laboratory Examination

    Changes of Triglyceride concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  41. Changes from baseline in CHOL of Laboratory Examination

    Changes of CHOL concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  42. Changes from baseline in TP of Laboratory Examination

    Changes of TP concentration (g/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  43. Changes from baseline in ALB of Laboratory Examination

    Changes of ALB concentration (g/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  44. Changes from baseline in UA of Laboratory Examination

    Changes of UA concentration (μmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  45. Pharmacokinetics:Cmax

    pharmacokinetic characteristics of LP-98 in infected patients:Cmax

    Time frame: Within 71 days after the first administration.

  46. Pharmacokinetics:AUC0-t

    pharmacokinetic characteristics of LP-98 in infected patients:AUC0-t

    Time frame: Within 71 days after the first administration.

  47. Pharmacokinetics:AUC0-∞

    pharmacokinetic characteristics of LP-98 in infected patients:AUC0-∞

    Time frame: Within 71 days after the first administration.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jul 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 25, 2026
StartActual
Jan 29, 2026
Primary completionEst.
Jul 10, 2026
CompletionEst.
Sep 25, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07433387
Lead sponsor
Shanxi Kangbao Biological Product Co., Ltd.
Collaborators
Institute of Pathogen Biology, Beijing, China
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Jan 29, 2026
Primary completion
Jul 10, 2026 (estimated)
Completion
Sep 25, 2026 (estimated)
Last update
May 11, 2026

Study contacts

Yuxian He, Doctor
Contact
yhe@ipb.pumc.edu.cn
+8613126823610
Fan Wang
Contact
wangfan3063@163.com
+8618534115213
Ping Ma, Doctor
principal investigator · Tianjin Second People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion